SynthesisDiabetes, obesity & metabolism2026
Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.
Synthesis in Diabetes, obesity & metabolism, 2026. The graph read 3 numbers from its abstract, feeding 2 cells of the map, but none could be read as for or against, so it casts no vote. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
Read, but not usablea number the graph found but could not read as for or against
Overall and serious adverse events were comparable between cagrisema and semaglutide, but combination therapy increased administration-site conditions [RR 3.27 (95% CI: 1.27, 8.46)] and nausea [RR 1.64 (95% CI: 1.01, 2.66)].
Overall and serious adverse events were comparable between cagrisema and semaglutide, but combination therapy increased administration-site conditions [RR 3.27 (95% CI: 1.27, 8.46)] and nausea [RR 1.64 (95% CI: 1.01, 2.66)].
Cagrilintide monotherapy had a higher risk of serious adverse events [RR 1.83 (95% CI: 1.03, 3.24)] compared to semaglutide.
clause the extractor read what became the number
Where it lands on the map
Rows are treatments, columns are outcomes. The coloured squares are the cells this paper feeds, coloured by the vote it casts there. Click one to jump to what this paper adds to it.
What it adds to each cell
For every cell the paper feeds: the belief in the claim with and without this paper, and this paper's estimate drawn against every other readable study in the cell. The ringed dot is this paper.
GIP/GLP-1 & amylin agonists×adverse events & safety
No readable resultOpen on the map →What to test next →4 readable studies in this cell: 2 favour the treatment, 2 find no difference, 0 favour the comparator.
This paper's own estimate is on a different scale from the rest of the cell, so it is not drawn here.
GLP-1 receptor agonists×adverse events & safety
No readable resultOpen on the map →What to test next →40 readable studies in this cell: 45 favour the treatment, 14 find no difference, 2 favour the comparator.
This paper's own estimate is on a different scale from the rest of the cell, so it is not drawn here.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Combination Pharmacotherapies for Obesity-Current Evidence and Future Directions.Endocrinology, diabetes & metabolism · 2026Review
- Metabolic Dysfunction-Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach.The Kaohsiung journal of medical sciences · 2026Review
- Efficacy and Safety of CagriSema for Metabolic Outcomes: Systematic Review and Pairwise Meta-Analysis of Randomized Controlled Trials.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The marked sentences are the ones the graph read a number from.
backgroundObesity is a complex chronic disease requiring effective long-term management. We performed a systematic review and meta-analysis to evaluate the efficacy and safety of cagrisema and cagrilintide monotherapy compared with semaglutide in individuals with obesity.
methodsWe searched MEDLINE, Embase, Scopus, Cochrane, and ClinicalTrials.gov for randomized controlled trials accessing cagrisema or cagrilintide versus semaglutide for weight loss. Efficacy outcomes were percentage change in body weight, absolute change in body weight, fasting plasma glucose, HbA1c, and BMI. Lipid parameters included total cholesterol, LDL-C, HDL-C, VLDL-C, and triglycerides. A random-effects model was used to estimate mean differences (MD) or risk ratios (RR) with 95% CIs.
resultsThree RCTs (n = 3545) were included. Cagrisema produced significantly greater percentage [MD -7.47% (95% CI: -10.58, -4.36); p < 0.001] and absolute [MD -7.60 kg (95% CI: -10.33, -4.86); p < 0.001] weight loss than semaglutide. Cagrilintide monotherapy weight loss was comparable to semaglutide. Lipids parameters were mostly similar between groups, though LDL-C was modestly higher with combination therapy versus semaglutide [MD 0.29 mmol/L (95% CI: 0.02, 0.55); p = 0.03]. Overall and serious adverse events were comparable between cagrisema and semaglutide, but combination therapy increased administration-site conditions [RR 3.27 (95% CI: 1.27, 8.46)] and nausea [RR 1.64 (95% CI: 1.01, 2.66)]. Cagrilintide monotherapy had a higher risk of serious adverse events [RR 1.83 (95% CI: 1.03, 3.24)] compared to semaglutide.
conclusionCagrisema is more effective than semaglutide in reducing weight and increasing glycemic control. Cagrisema is safe and has a comparable side effect profile to currently accepted treatments. This regimen has enormous potential in dual-agonist therapy for obese patients.
Indexed as
Identifiers
41834765What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.